🇺🇸 FDA
Pipeline program

UX701

UX701-CL301

Phase 2 gene_therapy active

Quick answer

UX701 for Wilson Disease is a Phase 2 program (gene_therapy) at Ultragenyx Pharmaceutical with 1 ClinicalTrials.gov record(s).

Program details

Company
Ultragenyx Pharmaceutical
Indication
Wilson Disease
Phase
Phase 2
Modality
gene_therapy
Status
active

Clinical trials